La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Immix Biopharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Immix Biopharma..

Immix Biopharma (NASDAQ:IMMX) Azioni, Catena delle Opzioni

Immix Biopharma

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Immix Biopharma Inc

News

Guidance

ADNT

Adient Sees FY25 Revenues Worth $14.1B-$14.4B Vs. $14.57B Estimate; Projects Adjusted EBITDA Worth $850M-$900M

Dividends

Icahn Enterprises Reveals Decision To Decrease Quarterly Distribution From $1.00 To $0.50 Per Depositary Unit

Earnings

Earnings Beats

Earnings Misses

Brookfield Renewable Q3 2024 FFO $0.42 Misses $0.43 Estimate, Sales $1.470B Beat $1.365B Estimate

EMKR

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

WIIM

ABNB

Airbnb shares are trading lower after the company reported worse-than-expected Q3 financial results.

<p>Icahn Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IEP#NASDAQ">IEP</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.21 by 76.19 percent. This is a 600 percent increase over losses of $(0.01) per share from the same period last year.</p>


Icahn Enterprises Q3 2024 GAAP EPS $0.05 Misses $0.21 Estimate

<p>Raymond James  analyst Andrew Cooper   upgrades Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) from Outperform to Strong Buy and maintains the price target from $120 to $120.</p>


Upgrades

Price Target

Analyst Ratings

Raymond James Upgrades Haemonetics to Strong Buy, Maintains Price Target to $120

<p>Adient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADNT#NYSE">ADNT</a>) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.52 by 30.77 percent.  The company reported quarterly sales of $3.562 billion which beat the analyst consensus estimate of $3.439 billion by 3.59 percent.  This is a 4.48 percent decrease over sales of $3.729 billion the same period last year.</p>


Adient Q4 2024 Adj. EPS $0.68 Beats $0.52 Estimate, Sales $3.562B Beat $3.439B Estimate

FTNT

Fortinet shares are trading lower. The company reported Q3 financial results.

<p>IEP proposed that Icahn Enterprises Holdings L.P. ("IEH") (or a subsidiary thereof) would commence a tender offer to acquire up to 15 million additional shares (the "Maximum Tender Amount") of common stock, par value $0.01, of CVR, for a purchase price of $17.50 per share.&nbsp;&nbsp;</p>


Offerings

Icahn Enterprises Delivers Proposal To Acquire Up To 15M Additional Shares Of CVR Energy Common Stock In Tender Offer For $17.50 Per Share

Block shares are trading lower after the company reported worse-than-expected Q3 revenue results.

<p>In a move to enhance its delivery capabilities during the holiday season, <strong>Walmart</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NASDAQ">WMT</a>) is rolling out new financial incentives for its independent delivery drivers. This initiative is part of Walmart&#8217;s broader strategy to improve the efficiency of online order deliveries from its U.S. stores to customers&#8217; homes.</p>
<p><strong>What Happened</strong>: <strong>Josh Havens</strong>, a spokesperson for Walmart, confirmed that the company is offering incentives and increased earning opportunities for its current drivers. However, specific details regarding these incentives were not disclosed, Reuters reported on Friday.</p>
<p>Walmart&#8217;s strategy aims to attract upper-income households and compete with<strong> Jeff Bezos</strong>&#8216; <strong>Amazon.com</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). The retailer leverages the Spark Driver app, enabling freelance drivers to deliver goods directly from stores, thereby boosting e-commerce sales and Walmart Plus subscriptions.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41794596/bitcoin-ethereum-dogecoin-slingshot-to-the-moon-after-trump-victory-but-sharp-correction-m?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Slingshot To The Moon After Trump Victory But &#8216;Sharp&#8217; Correction Might Be In Store: Analyst Views BTC Between $80-90K By End Of Year</a></strong></p>
<p>In addition, Walmart has slashed the Walmart Plus membership fee by 50% for the holiday season, offering it for $49 until Dec. 2. This move is anticipated to increase membership to 32 million by year-end, according to Emarketer. Meanwhile, Amazon offers a $99.99 fast grocery delivery service for its Prime members, who pay $139 annually.</p>
<p><strong>Why It Matters</strong>: The competition between Walmart and Amazon has intensified, with both companies vying for a larger share of the grocery market. In September, Amazon expanded its <a href="https://www.benzinga.com/news/24/09/40792054/amazon-targets-walmarts-grocery-market-with-expanded-prime-discounts">Prime member benefits</a>, offering significant discounts at Amazon Fresh stores. This move made grocery shopping more affordable and convenient for Prime members.</p>
<p>In October, Amazon further enhanced its Prime membership by <a href="https://www.benzinga.com/trading-ideas/24/10/41527960/amazon-vs-walmart-e-commerce-giant-offers-gas-savings-to-prime-members-ev-charging-discounts-in-lat">offering gas savings </a>and EV charging discounts, intensifying the battle for subscribers against Walmart.</p>
<p>Earlier in June, Walmart announced enhancements to its<a href="https://www.benzinga.com/news/large-cap/24/06/39387497/walmart-enhances-walmart-to-compete-with-amazon-prime-key-differences-unveiled"> Walmart+ membership program</a>, offering perks like free shipping, store delivery, and fuel savings, positioning it as a competitive alternative to Amazon Prime.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/equities/24/11/41763411/jeff-bezos-sells-214m-worth-of-amazon-shares-in-latest-stock-move-heres-how-much-he-still-owns?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jeff Bezos Sells $214M Worth Of Amazon Shares In Latest Stock Move, Here&#8217;s How Much He Still Owns</a></strong></li>
</ul>
<p><em>Image courtesy of Walmart, Inc.</em></p>
<p>This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <u><a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a></u></p>


Markets

General

AMZN

Walmart Offers New Holiday Bonuses To Independent Drivers As Competition With Jeff Bezos' Amazon Heats Up

<p>ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.09 by 22.94 percent. This is a 5.51 percent increase over earnings of $1.27 per share from the same period last year.  The company reported quarterly sales of $148.33 million which beat the analyst consensus estimate of $144.35 million by 2.76 percent.  This is a 12.52 percent increase over sales of $131.83 million the same period last year.</p>


ANIP

ANI Pharmaceuticals Q3 2024 Adj EPS $1.34 Beats $1.09 Estimate, Sales $148.33M Beat $144.35M Estimate

DKNG

DraftKings shares are trading lower after the company reported worse-than-expected Q3 revenue results and lowered its FY24 revenue guidance.

<p>As of Nov. 8, 2024, three stocks in the financials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.</p>
<p>The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. </p>
<p>Here's the latest list of major overbought players in this sector.</p>
<h3 class="wp-block-heading"><strong>Upstart Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>)</strong></h3>
<ul>
<li>On Nov. 7, Upstart reported quarterly losses of seven cents per share which beat the analyst consensus estimate for losses of 15 cents. Quarterly revenue came in at $162.14 million which beat the analyst consensus estimate of $150.22 million and is an increase over sales of $134.55 million from the same period last year. "With 43% sequential growth in lending volume and a return to positive adjusted EBITDA, we continue to strengthen Upstart's position as the fintech leader in artificial intelligence," said Dave Girouard, CEO of Upstart. "Even without a significant boost from the macroeconomy, we're back in growth mode." The company's stock gained around 29% over the past month and has a <a href="https://www.benzinga.com/quote/UPST">52-week high of $57.31</a>.</li>
<li><strong>RSI Value:</strong> 79.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li><strong>UPST Price Action:</strong> Shares of Upstart gained 2.8% to close at $55.47 on Thursday.</li>
</ul>
<h3 class="wp-block-heading"><strong>Toast Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)</strong></h3>
<ul>
<li>On Nov. 7, Toast reported better-than-expected third-quarter financial results. &#8220;Toast delivered a strong third quarter, adding approximately 7,000 net new locations, growing our recurring gross profit streams1 35%, and achieving Adjusted EBITDA of $113 million. We are well positioned to finish out the year strong and carry this momentum into 2025,&#8221; said Toast CEO and Co-Founder Aman Narang. The company's stock gained around 13% over the past month and <a href="https://www.benzinga.com/quote/TOST">has a 52-week high</a> of $33.00.</li>
<li><strong>RSI Value:</strong> 85.15</li>
<li><strong>TOST Price Action:</strong> Shares of Toast gained 1.7% to close at $32.67 on Thursday.</li>
</ul>
<h3 class="wp-block-heading"><strong>Flywire Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>)</h3>
<ul>
<li>On Nov. 7, Flywire reported better-than-expected third-quarter financial results and issued FY24 revenue guidance above estimates. &#8220;Our third quarter results highlight our ability to capture higher payment volumes with new and existing clients, signaling the growth potential within our accounts and verticals.&#8221; said Mike Massaro, CEO of Flywire The company's stock gained around 11% over the past month and has a <a href="https://www.benzinga.com/quote/FLYW">52-week high</a> of $31.54.</li>
<li><strong>RSI Value:</strong> 77.08</li>
<li><strong>FLYW Price Action:</strong> Shares of Flywire gained 2% to close at $18.30 on Thursday.</li>
</ul>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></strong></li>
</ul>


Short Ideas

Pre-Market Outlook

Trading Ideas

FLYW

TOST

UPST

Top 3 Financials Stocks That May Fall Off A Cliff This Month

AKAM

Akamai Technologies shares are trading lower after the company issued FY24 guidance below estimates.

PINS

Pinterest shares are trading lower after the company reported worse-than-expected Q3 EPS results.

<p>Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) reported quarterly sales of $1.136 million which beat the analyst consensus estimate of $300.000 thousand by 278.67 percent.  This is a 69.29 percent decrease over sales of $3.699 million the same period last year.</p>


OCGN

Ocugen Q3 Sales $1.136M Beat $300.000K Estimate

AXON

Axon Enterprise shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 revenue guidance above estimates.

Toast shares are trading higher after the company reported better-than-expected Q3 financial results.

Immix Biopharma Inc (IMMX) is around the middle of the Healthcare sector according to InvestorsObserver.IMMX received an overall rating of 49, which means that it scores higher than 49% of stocks. Additionally, Immix Biopharma Inc scored a 61 in the Healthcare sector, ranking it higher than 61% of stocks in that sector. IM

Will Immix Biopharma Inc (IMMX) Outperform the Rest of the Stocks in the Healthcare Sector?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Immix Biopharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/immx-stock-quote/"><strong>IMMX</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Immix Biopharma reported earnings per share of -24 cents. This was below the analyst estimate for EPS of -23 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/immx-stock-earnings-immix-biopharma-for-q4-of-2023/">IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Immix Biopharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/immx-stock-quote/"><strong>IMMX</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Immix Biopharma reported earnings per share of -22 cents. This was above the analyst estimate for EPS of -23 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/immx-stock-earnings-immix-biopharma-for-q1-of-2024/">IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024

Immix Biopharma, Inc. (IMMX) has shared an announcement. At Immix Biopharma, Inc.'s 2024 Annual Meeting, shareholders cast their votes on pivotal c...

Immix Biopharma Shareholders Back Growth and Governance Changes

Immix Biopharma, Inc. (IMMX) has received a new Buy rating, initiated by H.C. Wainwright analyst, Robert Burns. Robert Burns has given his Buy rati...

Buy Rating for Immix Biopharma Backed by Promising N-GENIUS Platform and Strong NXC-201 Sales Potential

Immix Biopharma doses first patient in U.S. AL amyloidosis trial

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Immix Biopharma, Inc. (IMMX – Research Report). The associated price ta...

Buy Rating Affirmed for Immix Biopharma Amid Promising NXC-201 Trial Outcomes and Market Potential

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Immix Biopharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/immx-stock-quote/"><strong>IMMX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Immix Biopharma reported earnings per share of -15 cents. This was above the analyst estimate for EPS of -21 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/immx-stock-earnings-immix-biopharma-for-q2-of-2024/">IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Equillium (EQ – Research Report), Foghorn Therapeuti...

Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)

Immix Biopharma, Inc. (IMMX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns f...

Immix Biopharma's Promising Therapeutic Candidate NXC-201 Fuels Buy Rating Amidst Strong Clinical and Financial Outlook

FHTX

IMMX

Press Releases

Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Health Care

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

Management

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Comments

Immix Biopharma

Immix Biopharma (IMMX) Opzioni

Immix Biopharma (NASDAQ:IMMX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO